Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Share-based Compensation: 2021-2025

Historic Share-based Compensation for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $12.7 million.

  • Prime Medicine's Share-based Compensation rose 86.71% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year increase of 25.00%. This contributed to the annual value of $26.1 million for FY2024, which is 87.40% up from last year.
  • As of Q3 2025, Prime Medicine's Share-based Compensation stood at $12.7 million, which was up 101.53% from $6.3 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Share-based Compensation peaked at $12.7 million during Q3 2025, and registered a low of $1.1 million during Q4 2021.
  • Its 3-year average for Share-based Compensation is $5.9 million, with a median of $5.7 million in 2025.
  • In the last 5 years, Prime Medicine's Share-based Compensation spiked by 209.88% in 2024 and then fell by 21.83% in 2025.
  • Over the past 5 years, Prime Medicine's Share-based Compensation (Quarterly) stood at $1.1 million in 2021, then surged by 132.52% to $2.6 million in 2022, then surged by 72.07% to $4.4 million in 2023, then skyrocketed by 34.14% to $5.9 million in 2024, then surged by 86.71% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $6.3 million for Q2 2025, and $5.7 million during Q1 2025.